Genocea Banking On Success With Herpes Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised $61 million in its February IPO, Genocea hopes 2015 will be another transformative year for the company, as it expects Phase II data for its herpes simplex virus vaccine, a potential first-in-class product.